Tamoxifen is one of the most common hormonal therapies for hormone-receptor-positive breast cancers (cancerous cells that feed off of certain hormones in the body). It’s usually taken as a pill once a day under the brand name Nolvadex. However, for people who have difficulty taking pills it can be given in a liquid form called Soltamox. Tamoxifen is often administered after surgery (as adjuvant therapy) to help reduce the risk of the cancer coming back. Sometimes it is started before surgery (as neoadjuvant therapy) as well. Tamoxifen works by blocking/stopping the effects of estrogen in a person’s breast tissue. This is because hormone-receptor-positive breast cancer feeds on hormones (like estrogen or progesterone) to grow. Tamoxifen is a hormonal therapy drug used to treat breast cancer, womb cancer and sometimes other cancers and conditions. It is best to read this information with our general information about hormonal therapies and the type of cancer you have. Like all cancer drugs, tamoxifen can cause side effects. Your cancer doctor, nurse, or pharmacist will tell you how often you will have it. Some of the side effects can be serious, so it is important to read the detailed information below. Your healthcare team can give you advice on how to manage any side effects. Tell your doctor or nurse straight away if you feel unwell or have severe side effects, including any we do not mention here. Your cancer doctor or nurse can explain the risk of these side effects to you. If you need medical attention for any reason other than cancer, always tell the healthcare staff that you are having this treatment. Tamoxifen can be given alone or with other types of treatment.
Metastatic breast cancer in women and men: 20 to 40 mg orally daily for 5 years; doses greater than 20 mg should be given in divided doses (morning and evening) DCIS following breast surgery and radiation: 20 mg orally daily for 5 years To reduce the incidence of breast cancer in women at high risk for breast cancer: 20 mg orally daily for 5 years Comments: -There are no data to support the use of this drug other than for 5 years. Uses: -Metastatic For metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, this drug is an alternative to oophorectomy or ovarian irradiation. Patients whose tumors are estrogen receptor positive are more likely to benefit. -Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, to reduce the risk of invasive breast cancer. -Reduction in Breast Cancer Incidence in High Risk Women: To reduce the incidence of breast cancer in women at high risk. "High risk" is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer greater than or equal to 1.67%, as calculated by the Gail Model. This content has not been reviewed within the past year and may not represent Web MD's most up-to-date information. To find the most current information, please enter your topic of interest into our search box. 14, 2007 (San Antonio) -- Even after treatment ends, Arimidex beats out tamoxifen in preventing breast cancer recurrence in women with hormone-fueled tumors. Updated results from this landmark trial also show that the increased risk of fractures associated with Arimidex therapy disappears after treatment stops. In the study, more than 5,000 women with hormone-receptor-positive tumors were followed for more than three years after treatment was stopped. The researchers show that an additional 25% of recurrences were prevented by Arimidex, compared with tamoxifen, says John F. Forbes, MD, professor of surgery at the University of Newcastle in Australia. During treatment, nearly 3% of women taking Arimidex had bone fractures vs. More than three years after treatment ended, the percentage was about 1.5% in both groups.
Tamoxifen, also known by the brand name Nolvadex, is one of the more commonly prescribed medications to prevent breast cancer recurrence, and when used appropriately, may reduce the risk of recurrence (of breast cancer coming back) by roughly 50 percent. The drug may also be used to reduce the chance that a woman will develop breast cancer in the first place, or to slow the growth of metastatic breast cancer. Tamoxifen works by binding to estrogen receptors on breast cells so that estrogen can't bind and stimulate growth. Learn about the potential side effects, how drug interactions may occur, and how tamoxifen differs from aromatase inhibitors. estrogen-like effects, depending on the particular type of tissue in the body where it acts. It is classified as a selective estrogen receptor modulator (SERM) along with the medication Evista (raloxifene). Tamoxifen is usually not considered beneficial for those who have estrogen or progesterone negative breast cancer. However, early detection and good treatments mean that survival rates have increased to about 80% in more developed regions. Animal studies led to the development of tamoxifen, one of the most successful treatments, and more recently Herceptin (trastuzumab) and aromatase inhibitors. The risk of developing breast cancer increases with age, like most cancers. However, there are several factors that affect the likelihood of developing breast cancer. The risk for developing breast cancer approximately doubles if a parent or sibling has been diagnosed with the disease, for example from a 1 in 10 chance to a 1 in 5 chance. This likelihood increases further if there have been several cases in the family or if it has been diagnosed at a young age. A very strong family history can indicate a faulty gene as a major factor.
Unusual side effects tamoxifen breast cancer. Stand heat, could inhibited by compounds known as cancer breast saponins that have been shown post, mi and heart failure because. Everyday Health Breast Cancer blogger Kathy-Ellen Kups had a different experience "After only three years on Tamoxifen, I was prescribed Arimidex but found those side effects of joint pain, fatigue.